PDS Biotechnology Corporation (PDSB)

Overview

PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company engaged in the development of innovative cancer immunotherapies. Based in Princeton, New Jersey, and founded in 2005, PDS Biotech specializes in advancing treatment options for various types of cancer through its proprietary immunotherapy platforms. The company's strategic collaborations with notable institutions, including the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH, underscore its commitment to pioneering the next generation of cancer treatments.

Products and Services

• PDS0101 (HPV16)

  This leading product candidate is currently in Phase II clinical trials and offers a novel approach as a first-line treatment for recurrent/metastatic head and neck cancer and other malignancies associated with the human papillomavirus (HPV). PDS0101 leverages the immune system to target and eradicate cancer cells, signifying a significant advancement in treating HPV-driven cancers.

• PDS0102

  An investigational immunotherapy utilizing the T cell receptor gamma alternate reading frame protein (TARP) for the treatment of prostate and breast cancers. PDS0102 is designed to activate the body’s immune response against tumor-associated antigens, offering a potentially powerful weapon against these prevalent cancers. Currently in preclinical trials, it represents a novel approach to immunotherapy.

• PDS0103

  Targeting ovarian, colorectal, lung, and breast cancers, PDS0103 is in the preclinical trial phase. It employs innovative technology to stimulate the immune system, aiming to offer a new therapeutic option for treating a range of complex cancers. The unique mechanism of action holds promise for improving outcomes in some of the most challenging to treat cancers.

• PDS01ADC

  A groundbreaking Interleukin 12 fused antibody-drug conjugate, PDS01ADC, enhances T cell proliferation, potency, and longevity within the tumor microenvironment. This investigational therapy is under development to transform cancer treatment by creating a more hostile environment for tumors through an enhanced immune response.

• PDS0104

  A Tyrosinase-related Protein 2 targeted immunotherapy, PDS0104 is designed to trigger a potent T cell attack against melanoma. As a novel investigational candidate, it represents a strategic shift towards targeted immunotherapies in melanoma treatment, focusing on stimulating the immune system to recognize and fight cancer cells.

• PDS0202

  This innovative investigational influenza vaccine is positioned to generate broad and robust antibody and T cell responses, offering protection against continually evolving strains of seasonal flu and potential pandemic threats. PDS0202 exemplifies the company’s expansion into vaccine development, leveraging its immunotherapy expertise to address viral diseases.